ArticleDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2014
[Management of cutaneous lymphomas].
Article in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- [Treatment of mycosis fungoides and Sézary syndrome].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous lymphomas challenge both researchers and physicians for several reasons. First, their pathogenesis has not been completely elucidated, which complicates the development of new curative therapies. DIAGNOSIS: Second, the diagnosis depends on a complex combination of clinic, histology, immunohistochemistry and molecular biology. Determination of the correct diagnosis is important for the patient and clinician because the different types of cutaneous lymphomas have very different prognoses and clinical courses, knowledge of which is essential for making treatment decisions. THERAPY: Third, no curative therapies for cutaneous lymphomas are available, so that the disease often relapses even during therapy. Thereby frequent changes in therapy are necessary, so that many patients receive a variety of treatments during the course of their disease. Many of the established therapeutic agents have a broad spectrum of side effects, so that special knowledge and experience with each agent is required, as well as careful monitoring. On the basis of more complex patient cases, general aspects of the difficult management of cutaneous lymphomas are discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.